The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Nat Nanotechnol. 2019 Dec;14(12):1084-1087. doi: 10.1038/s41565-019-0591-y.

Authors

Akin Akinc¹, Martin A Maier¹, Muthiah Manoharan¹, Kevin Fitzgerald¹, Muthusamy Jayaraman¹, Scott Barros¹, Steven Ansell², Xinyao Du², Michael J Hope², Thomas D Madden², Barbara L Mui², Sean C Semple², Ying K Tam², Marco Ciufolini³, Dominik Witzigmann³, Jayesh A Kulkarni³, Roy van der Meel³, Pieter R Cullis^{4

5}

Affiliations

¹ Alnylam Pharmaceuticals, Cambridge, MA, USA.
² Acuitas Therapeutics, Vancouver, BC, Canada.
³ University of British Columbia, Vancouver, BC, Canada.
⁴ University of British Columbia, Vancouver, BC, Canada. pieterc@mail.ubc.ca.
⁵ NanoMedicines Innovation Network, University of British Columbia, Vancouver, BC, Canada. pieterc@mail.ubc.ca.

PMID: 31802031
DOI: 10.1038/s41565-019-0591-y

No abstract available

MeSH terms

Animals
Drug Approval
Drug Carriers / chemistry
Drug Delivery Systems
Drug Development
Humans
Nanomedicine
Nanoparticles / chemistry
Polyneuropathies / drug therapy*
RNA, Small Interfering / administration & dosage
RNA, Small Interfering / chemistry
RNA, Small Interfering / therapeutic use*
Translational Research, Biomedical

Substances

Drug Carriers
RNA, Small Interfering
patisiran